益气维血联合铁剂对比生血宝联合铁剂治疗贫血相关疾病的临床疗效OACSTPCD

Objective To compare the clinical efficacy of Yiqiweixue tablets/capsules combined with iron supplements and Shengxuebao combination/granules combined with iron supplements in the treatment of anemia-related diseases.Methods A total of 916 patients with anemia-related diseases who had received treatment of Yiqiweixue(n=514)and Shengxuebao(n=402)for more than 1 year were selected from the information system database of 10 general hospitals in 6 provinces and cities across China from 2019 to 2021.Propensity score matching(PSM)method was used to balance the baseline characters of the observation and control group.After PSM,205 cases the observation group of Yiqiweixue tablets/capsules combined with iron for>30 days,while the control group of Shengxuebao combination/granules combined with iron for>30 days.The effectiveness indicators included cure rate(the cumulative incidence rate of patients whose hemoglobin(Hb)levels return to normal within one year),and efficacy rate(the cumulative incidence rate of patients whose Hb levels increase by more than 10g/L within one year),median time for Hb to return to normal and median time for Hb increase of more than 10 g/L.Safety indicators were changes of liver function ALT and AST.Results The cure rates of the two groups were 44.39%,with no statistically significant difference;the efficacy rate of the observation group was significantly higher than that of the control group(67.32%vs.54.63%,P<0.01);both the median time for Hb to return to normal and the median time for Hb to increase by more than 10 g/L were not significantly different in two groups,and no median relapse time was observed.The ALT and AST values in both groups showed no significant increase after treatment(P>0.05).Conclusions There is no difference in cure rate,time to cure and onset of actio between the 2 groups.Both treatments showed no impacts on liver function,but Yiqiweixue has sig-nificantly higher effective rate than Shengxuebao,which can be recommended for clinical use.